Business profile
Loading canonical business information.
About
Services
Products
Articles & research
Offers
Published by the business. Confirm current availability and terms with the business.
Browse productsPromotions
Published by the business. Confirm current availability and terms with the business.
Browse productsFrequently asked questions
Answers published by the business.
Published agent capabilities
Capabilities recorded in this listing. Their presence is not a live availability check.
AI-readable discovery
Read the structured business information and inspect the published discovery documents.
Machine-readable documents do not by themselves establish a live AI agent, checkout or business ownership.
Request a quote
Loading quote availability…
Sources
Report this listing
Tell us what needs reviewing. Removal requests are reviewed before any change is made.
Request removalProfile information
Publication, owner access and business registry verification are separate. Verification badges describe the checks completed; public references identify this listing.
Structured public business summary
Biosimilars Review and Report
Since 2013, Biosimilars Review & Report has tracked FDA biosimilar approvals, pipeline developments, clinical trials, biosimilar policy decisions, and market access trends in the United States.
Global
Business nature
- Primary business nature
- Not provided
- Customer market
- Not provided
Operating hours
Hours not provided.
Categories
- Healthcare & Medical (primary)
Products
- The 2023 Biosimilars Market Report
- The US Biosimilar Market: A History of Growth and Towards a Sustainable Future — The updated 2023 edition of BR&R's widely read Biosimilar Market Report series is a vital resource for those managing drug benefits, designing medical and pharmacy coverage policies, prescribing biologic medications, and those managing biosimilar and biologic assets. The US Biosimilars Market: A History of Growth and Towards a Sustainable Future provides a pragmatic framework on the performance of key biosimilar categories and the 2023-2026 pipeline.
Public contacts
- Public phone: 2013-2026
- linkedin: https://www.linkedin.com/company/106552976
- linkedin: https://www.linkedin.com/in/stan-mehr-b240157
- x: https://x.com/stanmehr
Declared AI capabilities
- Online checkout — Detected from public website navigation or discovery metadata.
- Online support — Detected from public website navigation or discovery metadata.
Directory status
Registry verification: Not Registry Verified
Directory score: 95
Public source evidence
- The Evolution of the Biosimilars Market | BR&R
- The 2023 Biosimilars Market Report | BR&R
- Biosimilars Report 2021 Archives | Biosimilars Review & Report
- Biosimilar Industry Report 2021 Archives | Biosimilars Review & Report
- New Expansion of Biosimilar Partnership: Samsung Bioepis and Teva Will Team up on Fasenra and Ilaris biosimilars, Plus 4 More | Biosimilars Review & Report
- About BR&R--Biosimilar Industry News, Research & Analysis